Insider · CIK 0001757122
Daniel Char
Files at IMGN (ImmunoGen, Inc.), EVLO (Evelo Biosciences, Inc.). First filing -, latest -.
In brief
Daniel Char files SEC Form 4 as officer at IMGN (ImmunoGen, Inc.), and also at EVLO (Evelo Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Daniel Char has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | IMGN ImmunoGen, Inc. | DDisposition to issuer Common Stock | -1,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | IMGN ImmunoGen, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | Feb 12, 2024 |
| Feb 12, 2024 | IMGN ImmunoGen, Inc. | DDisposition to issuer Restricted Stock Unitderivative | -22,825 | - | - | 0 | Feb 12, 2024 |
| Feb 1, 2024 | IMGN ImmunoGen, Inc. | AGrant or award Restricted Stock Unitderivative | +22,825 | $0.00 | $0 | 22,825 | Feb 5, 2024 |
| Nov 30, 2022 | IMGN ImmunoGen, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $5.19 | $2.1M | 400,000 | Nov 30, 2022 |
| Jul 19, 2022 | EVLO Evelo Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Oct 14, 2022 |
Questions about Daniel Char
Answered from the filings on this page, as of the latest one.
Is Daniel Char buying or selling?
Daniel Char has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Daniel Char's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel Char has 0.
Where does Daniel Char file Form 4?
Daniel Char has filed Form 4 at IMGN (ImmunoGen, Inc.) as SVP & CHIEF LEGAL OFFICER; EVLO (Evelo Biosciences, Inc.) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.